Anthony Michael Joshua
Garvan Institute of Medical Research · 806 works · 31,768 citations · h-index 72
Top works
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
- Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
- Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
- Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab
- [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
- Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL).
- Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma
- Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
- Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
- Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma
- Three-Color FISH Analysis of TMPRSS2/ERG Fusions in Prostate Cancer Indicates That Genomic Microdeletion of Chromosome 21 Is Associated with Rearrangement
- Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature.
- P0116 Updated clinical efficacy of the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in 411 patients with melanoma
- Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal Melanoma
- Evaluation of immune-related response criteria (irRC) in patients (pts) with advanced melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475.
- Pembrolizumab
- Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome
- Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab